| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| ln Vitro |
In H9c2 cardiomyocytes, notoginseng saponin R1 (2.5 -80 μM; 24 hours) inhibits hypoxia-reoxygenation (H/R), resulting in cell death, intracellular ROS buildup, and demyolysis of the mitochondrial membrane [1]. In a dose-dependent manner, notoginsenoside R1 (1-100 μM; 24 h) suppresses H/R-induced H9c2 cardiomyocytes [1]. In PC12 cells, notoginseng saponin R1 (10 μM; 24 h) reduces the formation of ROS, local damage, and MAPK activation produced by Aβ25-35 [2].
|
|---|---|
| ln Vivo |
When injected through the right jugular vein, notoginseng saponin R1 (5 mg/kg/h) suppresses the concentration of cytokines and mast cell degranulation while increasing erythrocyte velocity and reducing adherent leukocytes [3].
|
| Animal Protocol |
Animal/Disease Models: Male Sprague -Dawley (SD) rat (200-250 g) [3]
Doses: 5 mg/kg/h Route of Administration: 20 minutes before infusion of LPS via the right jugular vein Outcome: Improved LPS The induced shear rate in mesenteric venules was diminished to some extent. Attenuation of LPS-induced leukocyte adhesion to venous walls. Inhibits mast cell degranulation and cytokine elevation. |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Zebrafish are a commonly used model organism for studying vertebrate development and gene function, and in recent years have also been applied as a novel and powerful tool in drug development. In this study, researchers used zebrafish to investigate the metabolism of saponins isolated from Panax notoginseng—notoginsenoside (R1), ginsenoside (Rg1), and ginsenoside (Rb1). After exposing zebrafish to these three saponin compounds for 24 hours, high-performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI-MS) was used with a Zorbax C-18 column, and separation was performed using a binary gradient elution of 0.05% formic acid acetonitrile-0.05% formic acid aqueous solution. The quasi-molecular ions of the compounds were detected. Stepwise deglycosylation metabolites and hydroxylation metabolites of the three saponins were discovered, and these metabolites were consistent with the results of conventional metabolic analysis methods… |
| References |
|
| Additional Infomation |
Ginsenoside R1 is a ginsenoside derived from Panax notoginseng. Its structure is dammarane-type, with hydroxyl groups substituted at the 3β, 6α, 12β, and 20 pro-S positions. The hydroxyl groups at positions 6 and 20 are converted to the corresponding β-D-xylanopyranosyl-(1→2)-β-D-glucopyranoside and β-D-glucopyranoside, respectively, and a double bond is introduced at positions 24-25. It possesses multiple functions, including being a plant metabolite, antioxidant, neuroprotective agent, apoptosis inducer, and phytoestrogen. It is a β-D-glucoside, 12β-hydroxysterol, 3β-hydroxysterol, disaccharide derivative, ginsenoside, tetracyclic triterpenoid, and 3β-hydroxy-4,4-dimethylsterol. It is derived from the hydride of dammarane. Ginsenoside R1 has been reported to exist in Japanese ginseng, Panax notoginseng, and other organisms with relevant data. See also: Panax notoginseng root (partial).
Therapeutic Uses Ginsenosides |
| Molecular Formula |
C47H80O18
|
|---|---|
| Molecular Weight |
933.1273
|
| Exact Mass |
932.534
|
| CAS # |
80418-24-2
|
| PubChem CID |
441934
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1010.5±65.0 °C at 760 mmHg
|
| Melting Point |
218 °C
|
| Flash Point |
564.9±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.614
|
| LogP |
4.42
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
65
|
| Complexity |
1670
|
| Defined Atom Stereocenter Count |
25
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H](CO6)O)O)O)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C
|
| InChi Key |
LLPWNQMSUYAGQI-OOSPGMBYSA-N
|
| InChi Code |
InChI=1S/C47H80O18/c1-21(2)10-9-13-47(8,65-41-37(59)34(56)32(54)26(18-48)62-41)22-11-15-45(6)30(22)23(50)16-28-44(5)14-12-29(52)43(3,4)39(44)25(17-46(28,45)7)61-42-38(35(57)33(55)27(19-49)63-42)64-40-36(58)31(53)24(51)20-60-40/h10,22-42,48-59H,9,11-20H2,1-8H3/t22-,23+,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34-,35-,36+,37+,38+,39-,40-,41-,42+,44+,45+,46+,47-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2S)-2-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-6-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~107.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0717 mL | 5.3583 mL | 10.7166 mL | |
| 5 mM | 0.2143 mL | 1.0717 mL | 2.1433 mL | |
| 10 mM | 0.1072 mL | 0.5358 mL | 1.0717 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
